PIR and melanoma: We previously showed that we could abort the development of Vem resistance in mouse melanoma cells that harbor the prevalent BRAFV600 mutations by treatment (Foda and Neubig, 2023), in vitro, with the pirin-binding Rho/MRTF inhibitor CCG-257081.